|
MechanismFollistatin agonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I, double-blind, placebo-controlled, randomised, crossover study to assess the anti-inflammatory effects of orally inhaled PB01 following an inhaled lipopolysaccharide (LPS) challenge in healthy male volunteers.
Randomised, double-blind, placebo-controlled Phase I study to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of orally inhaled PB01 administered to healthy subjects.
100 Clinical Results associated with Paranta Biosciences Ltd.
0 Patents (Medical) associated with Paranta Biosciences Ltd.
100 Deals associated with Paranta Biosciences Ltd.
100 Translational Medicine associated with Paranta Biosciences Ltd.